This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
BioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Top
by Zacks Equity Research
A shift in BioScrip's (BIOS) strategy and the impact of implementing ASC 606 induce a Q2 earnings miss for the company. However, its progress with the new multi-faceted CORE plan is a positive.
Penumbra (PEN) Q2 Earnings & Revenues Top Estimates, View Up
by Zacks Equity Research
Penumbra (PEN) benefits from strong growth across all geographies and product lines in Q2.
Surmodics (SRDX) Beats Q3 Earnings Estimates, Raises '18 View
by Zacks Equity Research
Surmodics' (SRDX) third-quarter fiscal 2018 results benefit from increase in royalty and license fee revenues.
Teleflex (TFX) Q2 Earnings Top, Sales Lag, '18 View Bearish
by Zacks Equity Research
Teleflex (TFX) rides high on a strong year-over-year revenue improvement, banking on balanced segmental growth and wide geographical expansion.
Luminex (LMNX) Misses on Earnings in Q2, Margins Contract
by Zacks Equity Research
Luminex (LMNX) gains on ARIES and VERIGENE platforms in Q2; a solid guidance encourages.
Insulet (PODD) Q2 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
We are encouraged by the year-over-year improvement in Insulet's (PODD) results on solid uptake of Omnipod system in the United States in Q2.
Henry Schein's (HSIC) Q2 Earnings Beat, '18 EPS View Up
by Zacks Equity Research
All four of Henry Schein's (HSIC) operating segments recorded strong year-over-year growth in Q2.
Cardinal Health (CAH) Surpasses Earnings Estimates in Q4
by Zacks Equity Research
Cardinal Health (CAH) witnesses strong Q4, owing to strong sales at Pharmaceutical and the Medical segments. It provides an impressive FY19 view.
Bruker (BRKR) Q2 Earnings Meet Estimates, Margins Expand
by Zacks Equity Research
Bruker's (BRKR) strategic M&A activity is consistently raising investors' hopes. Further, the company's current focus on product development through higher R&D is an upside.
Quality Systems (QSII) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Quality Systems (QSII) gains from solid bookings in Q2; growing pipeline encourages.
Cerner (CERN) Beats Q2 Earnings Estimates, Bookings Rise Y/Y
by Zacks Equity Research
Cerner (CERN) gains from solid bookings growth in Q2; developments in the EHR front are promising.
Genomic Health (GHDX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
We are encouraged by the year-over-year rise in Genomic Health's (GHDX) revenues in Q2, driven by solid performances in the United States and internationally.
ResMed (RMD) Q4 Earnings & Sales Beat on Overall Growth
by Zacks Equity Research
ResMed (RMD) sees solid contributions from domestic and international businesses in Q4.
PRA Health's (PRAH) Q2 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
PRA Health (PRAH) sees year-over-year double-digit growth in earnings, revenues and net new business in Q2. However, increasing labor-related costs in the Clinical Research wing is a concern.
PerkinElmer (PKI) Q2 Earnings & Revenues Top, EPS View Up
by Zacks Equity Research
Solid performance by PerkinElmer's (PKI) DAS and Diagnostics arms is a key positive in Q2. The company saw strength across all major geographies in Asia, Americas, Europe and the BRIC nations.
IDEXX Laboratories (IDXX) Beats on Q2 Earnings, EPS View Up
by Zacks Equity Research
IDEXX Laboratories' (IDXX) stellar performance in Q2 was driven by strong sales at the CAG business.
NuVasive (NUVA) Q2 Earnings Meet Estimates, EPS View Down
by Zacks Equity Research
NuVasive (NUVA) expects robust demand for recently-launched products and positive surgeon conversion efforts as its new Lateral Single-Position Surgery procedure gains traction in the market.
Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Dips
by Zacks Equity Research
At the Home Health and Hospice divisions, Amedisys (AMED) gains traction from solid growth in Medicare and non-Medicare revenues.
Hologic (HOLX) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
Solid growth at Hologic's (HOLX) Breast Health and international business drives top line in Q3.
QIAGEN (QGEN) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
QIAGEN's (QGEN) year-over-year revenue growth in Q2 is encouraging. Expansion in operating margin buoys optimism.
Illumina (ILMN) Beats on Q2 Earnings, Lifts '18 Guidance
by Zacks Equity Research
Illumina (ILMN) gains on strong consumables growth across its sequencing portfolio with strength in all throughput categories in Q2.
Cardiovascular Systems (CSII) Beats on Q4 Earnings & Revenues
by Zacks Equity Research
Cardiovascular Systems (CSII) sees strength in Coronary device and peripheral device segments in Q4.
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Chemed (CHE) Beats on Q2 Earnings & Revenues, View Raised
by Zacks Equity Research
Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q2.
Outpatient & Home Healthcare Stock Outlook: Prospects Bright
by Zacks Equity Research
The outpatient and home healthcare companies are raking in huge profits of late, courtesy of AI-based treatment procedures that are easy, pocket friendly and ensure faster recovery.